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Abstract :  
Background and Aims: Few decades ago, idiopathic non-cirrhotic intrahepatic portal 
hypertension (NCIPH), a chronic microangiopathy of the liver, caused by arsenicosis from use of 
contaminated groundwater was reported from Asia.  This study aimed to see, if in the 21st century, 
arsenicosis was present in NCIPH patients at our hospital and, if present, to look for groundwater 
contamination by arsenic in their residential locality.  
Methods: 27 liver biopsy proven NCIPH patients, 25 portal hypertensive controls with hepatitis 
B or C related cirrhosis and 25 healthy controls, matched for residential locality, were studied. 
84% - 96% of study subjects belonged to middle or lower socio-economic category. Arsenicosis 
was looked for by estimation of arsenic levels in finger / toe nails and by skin examination. 
Arsenic levels in nails and in ground water (in NCIPH patients with arsenicosis) was estimated 
by mass spectrometry.  
Results : Nail arsenic levels were raised in 5 (10%) portal hypertensive study subjects [2 NCIPH 
patients (both had skin arsenicosis) and 3 portal hypertensive controls]. All these 5 patients were 
residents of West Bengal or Bangladesh. Skin arsenicosis was noted in 3 NCIPH patients (11%) 
compared to none of disease / healthy controls. Ground water from residential locality of 1 NCIPH 
patient with arsenicosis (from Bangladesh) showed extremely high level of arsenic (79.5 μg / L).  
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Conclusions: Arsenicosis and microangiopathy of liver, possibly caused by environmental 
contamination continues in parts of Asia. Further studies are needed to understand the 
mechanisms of such ‘poverty-linked thrombophilia’.   
Keywords : microangiopathy, endothelial activation, non-cirrhotic portal fibrosis, liver 
 
Introduction  
Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH) is an important cause of portal 
hypertension at our centre [1,2]. Non-cirrhotic portal fibrosis is a histological sub-type of the 
clinical entity, NCIPH, described more commonly in India [3-6].  
NCIPH is characterised by a chronic microangiopathy of small intrahepatic portal vein radicles, 
suggesting that gut derived insults may be driving this disease [7]. We have reported higher 
prevalence of gut disorders in NCIPH patients in UK and in India (celiac disease in 14% - 16% 
of patients, ulcerative colitis in 9%) [8,9]. We have also documented low levels of plasma 
ADAMTS13 {a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 
13; a von Willebrand factor (vWF) cleaving protease}, despite well-compensated liver functions, 
and raised plasma vWF levels in NCIPH patients.  ADAMTS13 to vWF imbalance may 
predispose to platelet-microthrombi formation in portal venules in response to gut derived insults 
– thus providing a mechanistic explanation for development of the isolated intrahepatic portal 
microangiopathy of NCIPH [10,11].  
Chronic arsenic ingestion, from contaminated groundwater [12], provides yet another example of 
gut derived insult driving NCIPH reported from various parts of India 1 – 5 decades ago [13-16]. 
At biopsy, hepatic arsenic content was higher in patients with NCIPH than in those with cirrhosis 
[13]. In 1988, investigators from W. Bengal reported 13 cases with non-cirrhotic portal fibrosis 
which were associated to drinking of water contaminated with arsenic and also associated with 
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high level  of arsenic  in liver tissue [16]. In a murine model, chronic arsenic ingestion caused 
significant hepatic fibrosis [17]. In contrast, from the West, arsenicosis causing NCIPH has been 
secondary to use of arsenic preparation (oral Fowler’s solution) to treat psoriasis [18-20].  
We conducted this study to look for evidence of chronic arsenic toxicity in NCIPH patients and 
for evidence of groundwater arsenic contamination causing the same, in present day Indian 
subcontinent.  
 
Materials and Methods : 
This hospital based case-control study was done to evaluate the association of arsenicosis with 
NCIPH.  We compared patients with NCIPH (cases) to patients with hepatitis B/C related 
cirrhosis with portal hypertension (disease controls) and healthy controls. The study subjects were 
recruited after obtaining their informed consent for the study. 
Recruitment of NCIPH cases and controls 
NCIPH was diagnosed as per published criteria [21], as follows: All NCIPH patients had 
esophageal or gastric varices (on endoscopy) with patent portal vein and hepatic venous outflow 
tract on Doppler ultrasound and an unyielding detailed clinical and laboratory evaluation for 
known etiologies of cirrhosis. All cases underwent liver biopsy which showed absence of 
advanced fibrosis / cirrhosis and of histological process suggesting alternate etiology, e.g. 
autoimmune hepatitis etc. None of the cases had any disease known to histopathologically mimic 
NCIPH e.g. sarcoidosis, schistosomiasis etc [21].  
27 consecutive NCIPH patients were recruited for the study. The route of liver biopsy in NCIPH 
cases (transjugular : 18; percutaneous : 6; per-operative : 3) was decided by clinician on a case-
to-case basis. In 3 patients, tru-cut and wedge biopsies of the liver were obtained during spleno-
renal shunt surgery. During transjugular liver biopsy, 3 (2-9); median (range) cores of liver with 
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size being 11 (4-19) mm and containing 8 (5-15) portal tracts were obtained. Similarly, during 
percutaneous liver biopsy 3 (2-3) cores of liver with size being 13 (8-13) mm  and containing 10 
(7-20) portal tracts were obtained. 
The liver biopsy in these 27 patients with NCIPH showed portal fibrosis, which was mild in 17 
and moderate in 2; mild peri-sinusoidal fibrosis (2) and incomplete septal cirrhosis (2). Other 
liver biopsy findings in NCIPH cases were - mild sinusoidal dilatation (13), portal vein ectasia 
with extension into parenchyma (8), atretic portal venules (2) and nodular regenerative 
hyperplasia (1).  
 Disease controls were consecutively enrolled patients with hepatitis B or C related cirrhosis with 
portal hypertension, diagnosed as per radiology, laboratory and endoscopy findings. Post liver 
transplant patients and patients with hepatocellular malignancy were excluded. Patients with 
acute illness were also excluded from the study. Healthy volunteers served as healthy controls. 
The controls were residents from similar locality as the cases. 
Besides routine clinical evaluation of study subjects, relevant laboratory evaluation was done as 
per case to case basis. Liver disease severity was assessed by Child’s score. As a marker of liver 
fibrosis, Aspartate aminotransferase to Platelet ratio index (APRI) was calculated [22]. Serum 
vitamin B12 assay was performed using electrochemiluminescence technique using a Roche E170 
modular system. Normal serum vitamin B12 levels are 200-950 pg/ml. Socioeconomic class of 
study subjects was assessed by modified Kuppuswamy score, utilising Indian consumer price 
index of August 2011, i.e. 194 [23,24]. 
Evaluation for arsenicosis  
Nail arsenic level was measured as per the previously described methodology [25]. In brief, 
clippings from finger and / or toe nails were collected from study subject, stored in labelled 
polyethylene bags at 4°c till tested. After removing the dirt on their surface manually, the nails 
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were washed using an ultrasonic bath in distilled water, and then in acetone. Overnight dried nail 
samples were then digested by microwave and arsenic levels measured by inductively coupled 
mass spectrometry. Quantitation was achieved by use of internal standards.  
Normal nail arsenic levels are 0.02-0.5 mg/kg of nail. Arsenic levels of >1.5 mg/kg of nail were 
considered high and indicative of over-exposure to arsenic in the recent past (9 months) [26]. 
All study cases underwent a thorough dermatological assessment for skin changes suggesting 
arsenicosis by a single dermatologist (R.G.), who was blinded to the nail arsenic levels. Skin 
arsenicosis was defined as typical skin lesions - hyperpigmentation and/or hypopigmentation of 
the unexposed body parts and/or keratosis of the palms/soles [26].  
Evaluation for thrombocytopenia associated with ADAMTS13-vWF imbalance in NCIPH 
patients with arsenicosis 
In NCIPH patients with arsenicosis, we assessed platelet counts, plasma activity of ADAMTS13 
and of vWF. ADAMTS13 activity was estimated in citrated platelet-poor plasma by an in-house 
collagen binding assay as previously described [11,27,28].  vWF activity by collagen binding was 
estimated in citrated plasma by a commercially available ELISA (Hyphen- biomed #RK038A, 
France). Normal plasma ADAMTS13 activity was 55-160% and normal plasma vWF activity 
was 50-150%. vWF:ADAMTS13 ratio was calculated. A ratio of ≥ 3 was considered as 
suggesting ADAMTS13-vWF imbalance. 
Statistical analysis  
All discrete variables are reported as numbers (percentage) and continuous variables as median 
(range). Non-parametric tests were used for comparison and a p-value of <0.05 was considered 
as significant. The study was approved by institutional review board and ethics committee. 
 
Results  
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During August 2011 - August 2013, consecutive patients attending the out-patient liver 
clinic fulfilling the inclusion and exclusion criteria were recruited for the study. 27 
NCIPH cases and 25 portal hypertensive disease controls (hepatitis B related cirrhosis : 
21; hepatitis C cirrhosis : 4) and 25 healthy controls were recruited. Demographic data of 
the 3 groups is depicted in table 1.  
Majority of participants in all the 3 groups were from eastern India. Most study subjects 
belonged to middle and lower socioeconomic class. The monthly family income for the 
NCIPH cases was Rs. 10,000; Rs. 3000-Rs. 40000 (median; range), for healthy controls 
was Rs. 3000; Rs. 1000-Rs. 25000) and for disease controls was Rs. 10,000; Rs. 2000-
Rs. 30000. On interview, none of the study subjects resided next to a mining area or were 
on long term complementary medications.  
Baseline liver disease status in study subjects :  
Table 2 depicts the severity of liver disease and portal hypertension in cases and disease 
controls. Platelet counts were similar in both the groups. Platelet counts were normal in 
1 case and in 3 disease controls. There was mild-moderate thrombocytopenia 
(>50000/cmm) in 12 cases and 13 disease controls and severe thrombocytopenia 
(<50000/cmm) in 14 cases and 9 disease controls. Liver disease was more severe in 
disease controls as compared to cases. Of the 8 NCIPH patients evaluated for vWF-
ADAMTS13 balance, 4 patients had low ADAMTS13 activity (<55%), 6 patients had 
high vWF activity (>150%) and 6 patients had vWF:ADAMTS13 ratio of >3. Low serum 
vitamin B12 levels were noted in 5 (19%) NCIPH cases as compared to nil disease control 
patients tested.  
Arsenic levels in nails :  
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Arsenic levels in nail clippings in cases (0.12, 0.023-2.24 mg/kg; median, range) were 
similar to that in disease controls (0.15, 0.01-0.64; p-value : 0.67) and  in healthy controls 
(0.1, 0.02-0.39; p-value : 0.74) (Figure 1). 
Arsenic levels in the nail did not correlate with platelet count, APRI, Child’s score and 
HVPG in NCIPH and disease controls (data not shown).  
Two NCIPH patients (both from West Bengal) and 3 disease controls (all from 
Bangladesh) had raised (i.e. > 0.5 mg/kg of nail) nail arsenic levels. One NCIPH patient, 
compared to none in both the control groups, had nail arsenic level of > 1.5 mg/kg.  
Skin changes of arsenicosis : 
Three patients with NCIPH had skin changes suggesting arsenicosis (Figure 2) as 
compared to none amongst the disease controls nor in healthy controls (p-value : 0.2), 
Table 3. These patients had predominant patchy hypo/ hyper pigmentation on the trunk 
and punctuate keratosis involving mainly the palms. One patient had extensive keratosis 
involving the feet as well. None of these patients had any feature suggesting psoriasis. 
Nail arsenic levels in these 3 patients with skin arsenicosis were 0.23, 0.8 and 2.24 mg/kg 
of nail.  
Details of patients with arsenicosis : 
The 3 NCIPH cases with arsenicosis belonged to Bangladesh (n=1) and West Bengal 
(n=2). All 3 patients were males with age of 46 (40-54) years. One patient presented with 
hematemesis (managed endoscopically) and the other 2 patients presented with 
splenomegaly and hypersplenism (managed conservatively). All 3 patients were in 
Child’s class A at presentation. There was no family history of similar disease in these 
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patients. The duration of symptoms prior to presentation to our centre in these 3 patients 
were 24 (12-36) months. 
The liver biopsy in these 3 patients (transjugular : 2; percutaneous : 1) showed mild portal 
fibrosis (2), mild sinusoidal dilation (2) and ectatic portal vein radicles (1) (Figure 3). 
HVPG measured in 1 patient was 7 mm Hg. They remain well with a follow up of 37 (34-
58) months (from time of initial presentation to our centre).  
The 3 NCIPH patients with arsenicosis were similar to the NCIPH patients without skin 
arsenicosis in their presentation, severity of liver disease and portal hypertension (HVPG 
and APRI) at presentation. The nail arsenic levels, on the other hand, were elevated in 
patients with skin arsenicosis (Table 4). 
In the 2 NCIPH patients with skin arsenicosis tested, plasma ADAMTS13 activity was 
reduced in 1 patient and normal in the other (46%, 66%), while plasma vWF activity was 
increased in both patients (393%, 257%). vWF:ADAMTS13 ratio in these two patients 
was 8.54, 3.89 respectively. 
Analysis of groundwater for arsenic contamination :  
Two NCIPH patients with arsenicosis brought groundwater samples obtained from wells 
(used for drinking water) their local residential locality. The assay for arsenic levels in 
these samples showed 79.5 µg/L (patient from Jessore, Bangladesh, with nail arsenic level 
of 0.23 mg/kg of nail), and 0.9 µg/L (patient from Murshidabad, West Bengal with nail 
arsenic level of 0.8 mg/kg of nail), Thus, in 1 patient from Bangladesh, the arsenic level 
in drinking water was much higher than the WHO guideline of < 10 µg/L and also the 
Indian standard of < 50 µg/L. All the 3 patients with arsenicosis were counselled about 
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the possible drinking water contamination with arsenic and about steps needed to rectify 
this. 
 Other associated disorders in patients with NCIPH : 
The other associated disorders in patients with NCIPH were – adult celiac disease (n=3; 
male : 2; age : 29, 28-37 years; median, range) and systemic lupus erythematosus (n=1; 
age : 31 year, female). In addition, one patient had history of pre-eclampsia during prior 
pregnancy. One patient developed glomerulonephritis 10 years after distal spleno-renal 
shunt surgery.  
 
Discussion 
In this study, we demonstrate clinical (dermatological) evidence of arsenicosis was 
present in 11 % (3 of 27) of NCIPH patients studied, increased nail arsenic levels in 10% 
(5 of 52) portal hypertensive study patients (2 NCIPH and 3 disease controls, all residents 
of West Bengal or Bangladesh which are plains fed by the Himalayan rivers - Ganges and 
Brahmaputra) and arsenic contamination of groundwater in the residential locality of 1 
NCIPH patient with arsenicosis (from Bangladesh).  Our report suggests continued 
environmental contamination as possible cause of arsenicosis associated with portal 
hypertension in the second decade of the  21st century – reported previously from the 
Indian subcontinent 10 – 50 years ago [12-16].  
We hypothesize that in a predisposed individual, chronic ingestion of arsenic may lead to 
occlusion of the intrahepatic small branches of portal venules, as is characteristic of 
NCIPH [29]. In our study, histological evidence supporting portal microangiopathy was 
10 
 
noted in liver biopsy in the 27 NCIPH patients in the form of sinusoidal dilatation, 
abnormal dilatation of portal venules, atretic portal venules and nodular regenerative 
hyperplasia. In our previous studies, we have documented low ADAMTS13 as a possible 
predisposition for development of NCIPH [10,11]. It is possible that NCIPH, an example 
of an isolated microangiopathy affecting the liver is caused by endothelial dysfunction 
(low ADAMTS13 levels and high vWF levels) which can accentuate platelet adhesion to 
endothelium, and small vessel occlusion inside the liver by platelet microthrombi [7]. In 
the present report, vWF-ADAMTS13 imbalance associated with thrombocytopenia was 
noted in 6 of the 8 NCIPH patients tested including the 2 NCIPH patients with arsenicosis 
(Child’s score of 5 and 6). Multiple animal studies have implicated the role of oxidative 
stress, activation of hepatic stellate cells, enhanced apoptosis of the hepatocytes and 
consequent collagen deposition in arsenic induced damage of the liver [30-33]. Arsenic 
also activates endothelium and increases vWF antigen expression on endothelial cells in 
vitro [34]. Mechanism of arsenic induced damage in mouse liver can be indirect by 
endothelial stimulation, rather than by direct cell damage [35].  We have not tested for 
other prothrombotic disorders in the study subjects, this is a limitation of our study.  
We have observed histological evidence of NCIPH characterized by evidence of liver 
fibrosis/ sinusoidal dilation in three portal hypertensive patients with arsenicosis 
diagnosed by presence of typical arsenical skin lesion [26]. Majority (90%) of NCIPH in 
the current study did not have arsenicosis, clearly indicating that multiple agents can 
contribute to causation of NCIPH. In our study, there was no difference in liver biopsy 
findings and clinical presentation of NCIPH patients with or without arsenicosis.  
In our study, the proportion of patients with increased nail arsenic was similar among 
NCIPH cases and in disease controls (with hepatitis B / C related cirrhosis and portal 
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hypertension) (Table 3). This suggests that arsenicosis could be a co-factor in 
pathogenesis (for example by causing intrahepatic endothelial activation leading to 
platelet plugging of small blood vessels in the liver) of NCIPH as well as of other causes 
of portal hypertension. Wanless et al [36], proposed that intrahepatic microvenular 
occlusion contributes to development and progression of cirrhosis [36]. Whether chronic 
arsenic exposure can accelerate this process in patients with cirrhosis of different 
etiologies remains to be studied.  
As per WHO criteria, we have defined arsenicosis as the presence of typical skin 
manifestations [26]. None of the patients had any other extra-hepatic manifestations of 
arsenicosis like respiratory symptoms or neuropathy. Nail arsenic levels reflect exposure 
to arsenic over previous 3-9 months and thus may only be helpful in ongoing chronic 
exposure. This may not necessarily exclude chronic exposure only in the remote past [26]. 
In acute arsenic poisoning, urinary arsenic level gives the clue to recent ingestion of 
arsenic [37].  
It is likely that chronic arsenic exposure by drinking contaminated groundwater is the 
cause of arsenicosis in our study patients. Analysis of groundwater for arsenic levels was 
performed in only 2 patients with NCIPH and arsenicosis and not in all other study 
patients (this is a limitation of our study). 
There are reports of increased metallic impurities, including arsenic, in complementary 
medicines [38,39].  None of our study patients gave a history of long-term intake of these 
medications.   
Groundwater contamination by arsenic in south and south-east Asia is well documented 
in Bangladesh, Eastern India (delta regions of Ganges, Brahmaputra) and Cambodia, 
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Vietnam (Mekong delta). Arsenic leached out from sediments in Himalayan Mountains 
into river water undergoes microbial reduction in anaerobic conditions [40].  Public health 
measures in place to combat this are - identifying and marking contaminated source, 
shifting to safe source of water wherever possible (e.g. adequately treated surface water, 
rain water harvesting or alternate ground water source, increasing the depth of the well 
etc.), continuous education / participation of the community and use of arsenic treatment 
plants/ filters [41,42]. As seen in our study, people from the poorer strata of society are 
still vulnerable to the effects of this environmental contamination (Figure 2, Table 4). On-
going arsenicosis in West Bengal and Bangladesh documented in this present report 
indicates the need to strengthen public health measures further. The ‘Clean Ganges’ 
project initiative of the Government of India, is likely to reduce environmental 
contamination in the Gangetic plains [43].   
It is postulated that genetic and environmental factors predispose to development of 
NCIPH [7]. In the past decade, few centres in India have reported decreasing incidence 
of NCIPH [4,5], this may reflect changing environmental factors in disease causation. 
Better sanitation and increasing use of bottled mineral water for drinking maybe some 
reasons for reduction of NCIPH in some parts of India. The current report on arsenicosis 
associated with NCIPH in patients living in areas fed by arsenic contaminated waters of 
Ganges – Brahmaputra rivers provides an explanation to why NCIPH is so common in 
India, a question asked by Professor Okuda many years ago [3].  
NCIPH is reported in patients belonging to poorer socio-economic strata [1]. Majority 
(84% - 96%) of study subjects in this study belonged to middle or lower socio-economic 
category. We have previously reported utility of low serum vitamin B12 level as a non – 
invasive marker of NCIPH [44], vitamin B12 deficiency was seen in 19% of NCIPH and 
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in none of the disease controls tested.  Further studies are needed to see if vitamin B12 
deficiency contributes to causation of NCIPH.   
In conclusion, we demonstrate that NCIPH associated with arsenicosis, possibly from 
contaminated groundwater, is an on-going problem in the Indian subcontinent in the 21st 
century. Environmental contamination causing chronic arsenicosis and NCIPH in West 
Bengal, India and in Bangladesh maybe considered an example of ‘poverty-linked 
thrombophilia’ causing chronic microangiopathy in the liver.  
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Figure legends 
 
Figure 1 : Arsenic level, as measured by inductively coupled mass spectroscopy, in nail 
compared in the various study groups. The nail arsenic levels in three NCIPH patients 
with skin arsenicosis are marked with asterisk (*). 
 
Figure 2 : Typical skin changes of arsenicosis (punctuate  keratosis (red asterisk *) of 
the palms) (Panel A) and liver biopsy depicting portal tracts with abnormally dilated 
portal venules ( Haematoxylin-Eosin10x; Panel B) in 46 year old male with non-
cirrhotic intrahepatic portal hypertension. He had raised nail arsenic level (0.8 mg/kg) 
and his Child’s score was 6, with platelet count : 60,000/cmm. He is a resident of West 
Bengal (India) and belongs to lower socioeconomic category (monthly family income 
Rs. 3000/-).  
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Table 1 : Demographic details of study patients  
 
Parameter 
NCIPH 
(n=27) 
Hepatitis 
B/C 
cirrhosis  
(n=25) 
Healthy 
controls 
(n=25) 
Age (years) 
35 (15-
64) 
36 (17-56) 
40 (20-
77) 
Sex 19:8 23:2 17:8 
States of 
residence 
West Bengal / Bangladesh 7/3 7/13 13/1 
Bihar/Chattisgarh/Jharkhand 7 2 3 
Other states of India 8 3 8 
Socioeconomic 
class* 
Upper 4 (16%) 1 (4%) 1 (8%) 
Middle 
16 
(64%) 
19 (83%) 4 (31%) 
Lower 5 (20%) 3 (13%) 8 (61%) 
 
NCIPH : Idiopathic non-cirrhotic intrahepatic portal hypertension 
*Socioeconomic class data available in 25 cases, 23 disease controls and 13 healthy 
controls. 
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Table 2 : Baseline laboratory assessment of liver disease in patients with portal 
hypertension (27 cases with NCIPH and 25 patients with hepatitis B/C related cirrhosis) 
Parameters NCIPH  
(n=27) 
Hepatitis B/C 
cirrhosis  
(n=25) 
p-
value 
Haemoglobin (g/dl) 12.3 (6.8-15.1) 12.7 (8.8-14.6) 0.4 
Platelet count (x105/cmm) 0.49 (0.17-
1.78) 
0.65 (0.14-1.57) 0.9 
Serum bilirubin (mg/dl) 1.3 (0.4-4) 1 (0.4-2.9) 0.3 
Serum albumin (mg/dl) 3.9 (2.9-5.5) 3.5 (2.1-4.7) 0.07 
International Normalised Ratio  1.2 (1-1.4) 1.2 (1-1.6) 0.005 
Esophageal Varices 
(small/large) 
4/22* 8/17 - 
Child’s score  5 (5-6) 5 (5-9) 0.002 
APRI 2 (0.6-4.7) 2.2 (0.5-11.4) 0.3 
HVPG (mm Hg)# 7 (3-12) -  
Serum vitamin B12 (pg/ml)^ 414 (107-
1128) 
808 (278-1833) 0.001 
ADAMTS13 activity (%)& 55.5 (39-86) - - 
vWF activity (%)& 260 (135-484) - - 
vWF:ADAMTS13 ratio& 4.1 (2.3-8.5) - - 
 
NCIPH : Idiopathic non-cirrhotic intrahepatic portal hypertension,  APRI : Aspartate 
aminotransferase to Platelet ratio index, HVPG : Hepatic venous pressure gradient; 
ADAMTS13: a disintegrin and metalloproteinase with thrombospondin type 1 motif, 
member 13; vWF: von-Willebrand factor 
*1 patient had no varices, but had spleno-renal collaterals on ultrasonography  
#HVPG was done in 13 NCIPH cases and none of the disease controls. HVPG was ≤5 
mm Hg in 2 patients and was >5 mm Hg in 11 patients  
^Serum vitamin B12 assay was available in 26 NCIPH patients and 12 patients with 
Hepatitis B/C cirrhosis 
&ADAMTS13 and vWF activity was available in 8 NCIPH patients {Child’s score of 
these 8 patients was 5 (in 7) and 6 (in 1 patient)} and none of the controls. 
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Table 3. Investigations into arsenicosis in study patients 
Skin changes 
of arsenicosis 
Nail arsenic 
content 
(mg/kg) 
NCIPH 
(n=27) 
Hepatitis B / C 
cirrhosis 
(n=25) 
Healthy 
controls 
(n=25) 
Present 
≤ 0.5 1* 0 0 
0.5-1.5 1# 0 0 
≥ 1.5 1# 0 0 
 
Absent 
≤ 0.5 24 22 25 
0.5-1.5 0 3* 0 
≥ 1.5 0 0 0 
 
NCIPH : Idiopathic non-cirrhotic intrahepatic portal hypertension; Patients from 
Bangladesh (*) and West Bengal (#). 
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Table 4 : Details of NCIPH patients with / without skin arsenicosis 
 
 NCIPH patients 
with skin 
arsenicosis 
(n=3) 
NCIPH patients 
without skin 
arsenicosis 
(n=24) 
p-
value 
Age (years) 46 (40-54) 33 (15-64) 0.016 
Male : Female 3:0 16:8 0.5 
From lower socioeconomic 
class# 
2 (67%) 11(50%) 1 
Residents of W. Bengal / 
Bangladesh 
3 7 0.02 
Presentation with 
hematemesis  
1 13 0.6 
Platelet counts (x105/cmm) 0.6 (0.4-0.9) 0.49 (0.17-1.8) 0.9 
Child’s score 5 (5-6) 5 (5-6) 0.4 
AST – Platelet Ratio Index 1.1 (0.9-2.6) 2.2 (0.6-4.7) 0.4 
Moderate portal/peri-
sinusoidal fibrosis on liver 
biopsy 
0 6 0.5 
Nail Arsenic level (µg/kg) 0.8 (0.2-2.2) 0.1 (0.02-0.3) 0.003 
Hepatic venous pressure 
gradient (mm Hg)* 
7 7 (3-12) 1 
 
#Socioeconomic class data was not available in 2 NCIPH patients without skin 
arsenciosis 
*Hepatic venous pressure gradient available in 1 NCIPH patient with skin arsenicosis and 
12 NCIPH patients without skin arsenicosis. 
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Figure 1 
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Figure 2a 
 
Figure 2b 
 
